Cancer of Unknown Primary (CUP) Expert Diagnosis, Molecular Profiling & Specialist Access

Cancer of Unknown Primary (CUP) is defined as metastatic cancer — cancer that has spread to one or more sites in the body — in which the original organ where the cancer started (the 'primary site') cannot be identified after a standard diagnostic evaluation including CT imaging and biopsy analysis. CUP is not a single cancer type but a heterogeneous group sharing the common feature of undetected primary origin. Unlike most cancers where the primary site is known (e.g. 'Stage IV lung cancer with liver metastases'), CUP is defined by the absence of a confirmed primary. This creates diagnostic and treatment complexity, though modern molecular profiling can now identify the probable tissue of origin in most cases.

Several biological mechanisms are thought to explain occult primary status in CUP. In some cases, the primary tumour may have spontaneously regressed or been controlled by the immune system after seeding metastases — leaving behind active metastatic disease without a detectable primary. In others, the primary tumour may be too small to detect with current CT or PET-CT resolution at the time of presentation. Some CUP cases may involve primary tumours arising in locations that are not routinely imaged or endoscoped. Modern molecular profiling (NGS with tissue-of-origin analysis) can now assign a probable primary site in approximately 70–80% of CUP cases even when imaging cannot detect the primary.

Molecular profiling in CUP involves comprehensive genomic sequencing (NGS) and/or RNA expression analysis of the tumour biopsy to identify two things: first, the probable tissue of origin (which organ the cancer is most likely to have originated from), and second, any actionable genetic mutations or alterations that can be targeted with approved drugs (such as NTRK fusions, BRAF V600E, MSI-H, HER2 amplification, and others). Identifying a probable tissue of origin enables treatment with regimens that are matched to that specific cancer type — which is more effective than generic empirical chemotherapy for most patients. Actionable targets can be treated with approved targeted therapies regardless of where the tumour originated.

Yes — approximately 15–20% of CUP patients fall into 'favourable subsets' that have specific, highly effective treatment patterns. The most important are: (1) Young men with undifferentiated midline carcinoma, which may represent an extragonadal germ cell tumour — treated with BEP chemotherapy with high cure rates. (2) Women with adenocarcinoma in axillary lymph nodes — treated as occult breast cancer with surgery, radiation, and systemic breast cancer therapy. (3) Women with peritoneal carcinomatosis and papillary serous histology — treated as primary peritoneal/ovarian cancer with platinum-taxane chemotherapy. (4) Squamous cell carcinoma in cervical lymph nodes — treated with combined modality head and neck oncology approaches. Correctly identifying and acting on these favourable subsets is one of the most important steps in CUP management.

For patients with CUP where molecular profiling does not identify a primary site or actionable target, empirical combination chemotherapy is used. The most commonly used regimens include carboplatin-paclitaxel (well-tolerated and broadly active), carboplatin-gemcitabine (particularly in older patients or those with reduced performance status), and platinum-docetaxel. Responses to empirical chemotherapy occur in a proportion of patients. However, patients who respond to empirical chemotherapy are encouraged to have molecular profiling performed to see whether a site-specific or targeted therapy could provide a better outcome.

Yes, in certain molecularly defined CUP subsets. Pembrolizumab (Keytruda) is FDA-approved for any solid tumour with MSI-H/dMMR (mismatch repair deficient) microsatellite instability, and for tumours with high tumour mutational burden (TMB-High, ≥10 mut/Mb). These tumour-agnostic approvals apply directly to CUP patients with these features identified on NGS profiling. Approximately 5–10% of CUP cases are MSI-H/dMMR. Broader immunotherapy combinations in unselected CUP are being evaluated in clinical trials.

Multiple FDA-approved tumour-agnostic targeted therapies are applicable to CUP when the relevant molecular alteration is identified by NGS profiling: larotrectinib or entrectinib for NTRK gene fusions; dabrafenib + trametinib for BRAF V600E mutations; selpercatinib for RET rearrangements; pembrolizumab for MSI-H or high TMB; trastuzumab deruxtecan or trastuzumab-based therapy for HER2 amplification; and PARP inhibitors (olaparib, niraparib) for BRCA-mutant ovarian-pattern CUP. These agents are approved based on molecular target rather than primary tumour type, making comprehensive NGS profiling at diagnosis essential for all CUP patients.

Not at all. While CUP historically carried a poor prognosis with empirical chemotherapy, the field has changed substantially. Patients in favourable subsets may achieve outcomes similar to Stage II–III of the relevant primary cancer. Patients with actionable molecular targets can receive highly effective targeted therapies. Even in unfavourable unclassified CUP, empirical chemotherapy produces responses in a proportion of patients, and immunotherapy and targeted therapy clinical trials are expanding options. The most important step is access to comprehensive molecular profiling and specialist CUP multidisciplinary review, which collectively identify the treatment approach most likely to be effective for each individual patient.

Yes. CancerFax supports patients with CUP by reviewing pathology reports and IHC panels, coordinating specialist second opinions from expert oncologists and molecular pathologists experienced in CUP management, facilitating access to comprehensive NGS-based molecular profiling and tissue-of-origin analysis services, identifying actionable molecular targets and their corresponding targeted therapies, and connecting patients with specialist CUP multidisciplinary clinics and clinical trial programmes in India and internationally. Please share your medical records via the CancerFax portal or contact our team to begin.